{"name":"Cinclus Pharma Holding AB","slug":"cinclus-pharma-holding-ab","ticker":"","exchange":"","domain":"cincluspharmaab.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"Linaprazan glurate - Low dose","genericName":"Linaprazan glurate - Low dose","slug":"linaprazan-glurate-low-dose","indication":"Gastroesophageal reflux disease (GERD)","status":"phase_3"},{"name":"Linaprazan glurate - High dose","genericName":"Linaprazan glurate - High dose","slug":"linaprazan-glurate-high-dose","indication":"Gastroesophageal reflux disease (GERD)","status":"phase_3"},{"name":"Lansoprazole - Marketed approved dose","genericName":"Lansoprazole - Marketed approved dose","slug":"lansoprazole-marketed-approved-dose","indication":"Gastroesophageal reflux disease (GERD)","status":"phase_3"}]}],"pipeline":[{"name":"Linaprazan glurate - Low dose","genericName":"Linaprazan glurate - Low dose","slug":"linaprazan-glurate-low-dose","phase":"phase_3","mechanism":"Linaprazan is a potassium-competitive acid blocker (P-CAB) that reversibly inhibits the gastric H+/K+-ATPase pump to reduce gastric acid secretion.","indications":["Gastroesophageal reflux disease (GERD)","Peptic ulcer disease","Acid-related disorders"],"catalyst":""},{"name":"Linaprazan glurate - High dose","genericName":"Linaprazan glurate - High dose","slug":"linaprazan-glurate-high-dose","phase":"phase_3","mechanism":"Linaprazan is a potassium-competitive acid blocker (P-CAB) that reversibly inhibits the gastric H+/K+-ATPase pump to reduce gastric acid secretion.","indications":["Gastroesophageal reflux disease (GERD)","Peptic ulcer disease","Acid-related disorders"],"catalyst":""},{"name":"Lansoprazole - Marketed approved dose","genericName":"Lansoprazole - Marketed approved dose","slug":"lansoprazole-marketed-approved-dose","phase":"phase_3","mechanism":"Lansoprazole inhibits the proton pump in gastric parietal cells, reducing gastric acid secretion.","indications":["Gastroesophageal reflux disease (GERD)","Peptic ulcer disease","Zollinger-Ellison syndrome","Acid-related dyspepsia"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxPTnhfa01fOVBVaFJaT2J6NWJ2WHU3TzQyU1dleHg3ZUNxNHAyb0JEVFM5dThlNUhaSFNDT1NXM1NPd0NxSGxCUmRiMDNwcG04RmpZRTZSSDRySEwwZFRjTU81Um1xTnhnNWxnWVFNQkE3bkVsNHpOWEpxZ1lkb2NGZU9zcUxVcFVhWXF1LWJ4QUYwVXd0WS1HX0pGUWM2VnBVV25jWnZB?oc=5","date":"2026-04-06","type":"pipeline","source":"TradingView","summary":"Working capital per share of Cinclus Pharma Holding AB – FWB:J8P - TradingView","headline":"Working capital per share of Cinclus Pharma Holding AB – FWB:J8P","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYkFVX3lxTE5nbVB1Y3JaaXpCNGE5OWZqNmR2YTZJLVM4TVJMRk1yOVJvMTdDaGloNldWdVRrS0NreWgwWF9oRzM4WFoyT0JvSWhLX2pqWGhKU0VzemJNbkVTSHJHUER5ZmhR?oc=5","date":"2026-04-02","type":"pipeline","source":"sg.finance.yahoo.com","summary":"Cinclus Pharma Holding AB (publ) (J8P.F) stock price, news, quote and history - sg.finance.yahoo.com","headline":"Cinclus Pharma Holding AB (publ) (J8P.F) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxNRVRybVktOU5yNVBfb1pNVndJblRSdjEtcXpNdWtzVS0tcS13Q3JlQnB0a1VfOFpCWWNreFJqVk8xZ0ZfMUh5TnJOY3VZTzdaemRmTW1MeXB6MTE4dHllLWlqZ2tQUk1rczZPbFlacFhsTW1Sc2FwdXdFRXN3aU53eHloVGZOdFZQNjliUW4tNnBHanl3S2FWZlkxNEhMOXcxS01DRWdaajlLNDdmdlZZUGdVNm9pbHJiS2Z6Z2NLWVlyeE9FelFn?oc=5","date":"2026-03-31","type":"pipeline","source":"TipRanks","summary":"Cinclus Pharma Ramps Up Investor Outreach Ahead of Late-Stage GERD Drug Push - TipRanks","headline":"Cinclus Pharma Ramps Up Investor Outreach Ahead of Late-Stage GERD Drug Push","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxNbVNWOEhZWXBEUE5YaURGT3JUREV6ZUZmc2c4djc1NjhKNHFMaldjWGhaWjhvMmttTW1TblYtZ0hTU2RsS2pHbjlYSGpsdXNtMDZYWHlsZ0FfT05NbTIwNFNSVWtMdVVqbURjM2hWOTQyeUwzLXNOS1VTUURGeHgyNXVuQl9ER2tGYWRhVlprOTNjeW9hNnA1WG9tYmZRZFhZMHY2aVh4R3RMZHFORHprcmU2cTFBaXljaWZvSnk0SFR6ZHkySlNn?oc=5","date":"2026-03-31","type":"pipeline","source":"TradingView","summary":"Cinclus Pharma to participate in upcoming investor conferences - TradingView","headline":"Cinclus Pharma to participate in upcoming investor conferences","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_wFBVV95cUxQakNLYVFXOHFoR0FOWFdQcWdlcUk3V0NTcTRDckpCekduMWU5dnVpTTdDcklKOXN1YURRSlo3bENGcTFETXZoSWFBSE0wQkFoSVhkVTNGRmFJTkdnNDB0Y1pNZTdJNFFMT3EwTGk3WDFVNkFvOTJuUGp5ZlFTUFVTT04wWEpHbnI3RUR0M3BPQXh5ZWllbjdkcERxV1VValAxNC1RZTgtSDRadkRMOFFqbXVLR0l4aTZRVnpoQnlLc0cwQWthMDBaWjB4RnQxZFJCdWQwLTlnRHIxYV96X3ViVS11a3RiN2VGNng3MFdCblN5bEpvRUsxS0lYS2ZGbGM?oc=5","date":"2026-03-25","type":"pipeline","source":"Finansavisen","summary":"Interim report January-June 2025 - Strengthened position for future value creation - Finansavisen","headline":"Interim report January-June 2025 - Strengthened position for future value creation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxOVkR4aGpmaDVsZkNKMFVDNjZYYXdUTUU3ZkJtWUljaWIxdmFrYUlSYXJCRG1jUElQUC1LeVRDY1lDQmZfdDNRbTVGY1hZM1Qydk9qOUs0d29XbmlnNEFaVUE2Vnl4SlgwbFhRMklraWtNNVpkSm13VF8xVi1fcUpGZWtnYUxwaXhNTTZ2eUVoTm9RSU5wMXV1MjNaVEt5UURQZm1SdTRBU2FCaEV6bU1CRnU5SlJiSXpUX0FLcVhKU1pseXM?oc=5","date":"2026-03-13","type":"deal","source":"GlobeNewswire","summary":"Claret Capital Partners invests €28M in Cinclus Pharma - GlobeNewswire","headline":"Claret Capital Partners invests €28M in Cinclus Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4gJBVV95cUxPME0tQU5xYXRyZGRhVUhpX24wQUdieDFBdzBLUkZBaGRWVU10TVUwOFpSejc5Y2d1Ti11eldnNV9ZU2R3TGExbVBUWXdIY01YYmJ5aUJwaXN1cUp5U250SlBZYzU2LUI0bmtvUENyVTN0RmFZamxURXFWajZlMUl0MHJQYVFCTzZLSFJyTFp1RW53VGhjTHJNZWluanp5dUFQY05xMFpTeWcwQmt6WkdsN29PN1A0WXZzb1k4RDNFcllSbUtrLTVLNVlsMVEySG82UWxRSm9Ya29feGh0VzRkME1VaUxPR3lTUlZBbnJwaUphWjA1VUZiZGx5cC10LXZYNmcwdE5Eak9uLVppV0pfekxBblF5SG10N1Z1eGhZRVdyM0s5YVFsVEpNMWFxeml0NjctT3BocEF0M2tTbXZYcUtrTkR2MmJkMU1NdVN5VFc1V19aaFJZSTNmOVNBVDgxZUE?oc=5","date":"2026-02-23","type":"regulatory","source":"Finansavisen","summary":"Cinclus Pharma: FDA Determines That a Single Pivotal Study Is the New Standard for Market Approval in the US – Positive for the Company’s Phase III Program - Finansavisen","headline":"Cinclus Pharma: FDA Determines That a Single Pivotal Study Is the New Standard for Market Approval in the US – Positive ","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxQd2dtck5JY0hYRFFFUlpRU08yQ3Qydzlha21zY0JneHU3OXdXcWZfZ0JLamFmdm5EUGMxQll0a3huMEpvcWZRb0I1b2dPYS1nRUNmcGVJOHhFUVMzQy1zTXAzNVBNZ3VEUHdOMWZnajktS0NON3Y3Qks1bkRFVzg1YTI3RnhMcHVQWE11MHhXdlZPcHhYMkkzU0s1aXdISXJVWk1iZXNXcXpCdHRXdmtpNnFEWDhKVGxxeGpVNkgyQUpYZU5jTF9ScW93VQ?oc=5","date":"2026-02-22","type":"regulatory","source":"TipRanks","summary":"Cinclus Pharma Gains Boost as FDA Backs Single Pivotal Study Path for GERD Drug - TipRanks","headline":"Cinclus Pharma Gains Boost as FDA Backs Single Pivotal Study Path for GERD Drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgJBVV95cUxNMjZfUHdYcnRzb0JEXzBYQkRza29yaWZRNG1fWmllV0FEWjBzbXkzenBUMV9NNko5eERxUkZMZ1MzVlBIZlR4WU1aMmFPNjB6SUVBQUNkdE9STDdfVU9CTTJBUTJjbjhOSThHdEhEMk42c1Y0alR4NGZUOEJUek1yR2VGMWpFcHBZTW93NUUxYWg4VUp5VF9FaXNiSF9neXI4TUdibmt1WUNVbF9HUThicXNQQ0loR0VLNlhiQWJMVUM2SVh2RGtiX0Y3TmozVnZfWFF5WUdKZThYa3JkSVBJMGwtX3pRYnZzQW5RMTVubEtYcGVXal9iSnpqc2xGcHdIbWNFM3pqNzZiMkN5YlVGZFN3?oc=5","date":"2026-02-13","type":"regulatory","source":"Finansavisen","summary":"Cinclus Pharma receives positive assessment of its nonclinical development plan from the FDA - Finansavisen","headline":"Cinclus Pharma receives positive assessment of its nonclinical development plan from the FDA","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAJBVV95cUxQbmlfczJxQkNHMjR2RlRSRkFBUFp0bGZ5WldXVmJpTHpoWXJOX1BZOGYyWVVjUnBSUUM3UVVrVUx6ZGtWNUpOQ0JkNzJPdHJ2NWxyMDkxQ3ltaEtLN0VweXFkeVJEUFpwa0hLUkwtZVprYkd5Skp2UWhQNHJlVHoycHhNUXhzbXREZWUzYjVSb0p1UFp1WGppUl9MNVNZeFZiY0FPeUpnSFFkYkhCSml0cEJyNTRwendaTjA2Qi1wUHE2aDRzbi1TczNDWGpWQUJCbXNtRGhJYkJVWDZHMnIxTHQ5Tlh3dUFvcVlFSzd0RkFNczNlX2JfM29ackZaalF1N0tNam5XVDFfaW13X1YtQWpNSlBoUG5JTjhzMHgyeVY?oc=5","date":"2026-02-10","type":"regulatory","source":"Finansavisen","summary":"Cinclus Pharma receives regulatory support – EMA provides positive feedback on CMC for linaprazan glurate - Finansavisen","headline":"Cinclus Pharma receives regulatory support – EMA provides positive feedback on CMC for linaprazan glurate","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwJBVV95cUxPS0ZOZU1ScEx1ZlBscU9QYmVSdzZQSnNWWlBIbjhCVEpiSldmVDBJVm00UVNLV3lDOW5pWU5SOEZrMnQ1RFp6YXBLODJzS1hFVXhmNlhnX3ZlelRtV3FPOFhKS2NWZWxUVDd0TVR1LUJ5OS1RcFN1LW1fTHNNcTRGbzliWGdHdGlxSllibWgzYWlya1Jlc0dKSUU5V19ta3RFSjA0bTZhQnpSYzRodldWMkR0SXNRNi1ONzVXUm9VT0JPbzJtclFHOC00aFczbGY0UGNqUm5RVlRxLUtJd0pzLXNEVUJqU2RPNDFPNkFfWUY3NUpsOVJyWXczWHlCVkhNMmdyNHlmR2dGbEY4bHZxT2tyTlAwenlTWVNN?oc=5","date":"2026-01-19","type":"pipeline","source":"Finansavisen","summary":"Resolutions at the Extraordinary General Meeting in Cinclus Pharma Holding AB (publ) on 19 January 2026 - Finansavisen","headline":"Resolutions at the Extraordinary General Meeting in Cinclus Pharma Holding AB (publ) on 19 January 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9gFBVV95cUxPY3dEMEIwYnZxX0duWDlGRGFiQjgwZkx4MHJtUEQwa09TaWpfVF9oTTI3cGtxUWJNWTBOU1k4Mkg5aVhacDlKeER2dGxxY0owRlk5cm1peEp6NmlBUDlWcTlySnRBWENzcl9tQTNfZU0xVWhoUGJrMWg0WmRTNl9EUVdDaHd4YVp4Yjdla1JQUGxTbkplWjR4dHhZZmRfaEZxcGk4WjFmMjNNdElHMjZQU2NjSUJiSFNHS0lFUWpXRkNHcVBDWnFIWnctcVlpd2Q1VVdwbl94YzZSY0t6TkpNS1ZCRHBHaGRfMDQ4N0RHQWNULXZGdmc?oc=5","date":"2025-12-08","type":"pipeline","source":"Finansavisen","summary":"Notice of Extraordinary General Meeting in Cinclus Pharma Holding AB (publ) - Finansavisen","headline":"Notice of Extraordinary General Meeting in Cinclus Pharma Holding AB (publ)","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_3":3},"enrichmentLevel":0,"visitCount":7,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}